Sold out
1 1

ACE-031

ACE-031

$170.00 USD
$170.00 USD

Overview

ACE-031, also known as ramatercept or ACVR2B-Fc, is a recombinant fusion protein consisting of the extracellular domain of human activin receptor type IIB (ActRIIB) fused to the Fc portion of human IgG1. It functions as a soluble decoy receptor that binds myostatin (GDF-8) and other TGF-β superfamily ligands (activins, GDF-11), preventing their interaction with endogenous receptors. It is widely used in laboratory and preclinical research as a model compound to investigate muscle hypertrophy, muscle regeneration, bone metabolism, and related signaling pathways in various in vitro and animal model systems.

 

Research Applications (Observational Data from Published Studies) The following points summarize observations reported in scientific literature from preclinical (in vitro/animal) and human clinical trials and are provided solely for informational and research-planning purposes:

  • Muscle Growth and Hypertrophy Research: In rodent models, non-human primates, and Phase 1/2 human trials in healthy postmenopausal women, ACE-031 administration produced significant increases in lean body mass (+3–5% within 29 days at doses 1–3 mg/kg), thigh muscle volume, and muscle strength biomarkers through myostatin inhibition.
  • Bone Metabolism Studies: In ovariectomized rodent models of osteoporosis and Phase 1 human studies, ACE-031 markedly increased bone mineral density (BMD), bone formation markers (P1NP), and trabecular bone volume via inhibition of activin signaling.
  • Metabolic and Fat Mass Research: In obese and insulin-resistant rodent models and early human data, ACE-031 reduced fat mass, improved insulin sensitivity, and increased energy expenditure secondary to elevated muscle mass.

 

Important Legal Disclaimer For laboratory research use only. Not for human or veterinary use. Not for diagnostic, therapeutic, cosmetic, or food purposes. Not approved by the FDA or any regulatory agency. Researchers are responsible for compliance with all applicable laws and institutional guidelines.

 

Chemical Information

  • Sequence: Not applicable (recombinant fusion protein: extracellular domain of human ActRIIB (Ala20–Arg134) fused via linker to human IgG1 Fc domain with mutations for reduced effector function)
  • Common Name: Ramatercept, ACE-031, ActRIIB-Fc
  • Molecular Formula: Complex glycoprotein (C₃₄₃₀H₅₃₃₄N₉₄₆O₁₀₀₈S₃₂ approximate, glycosylated)
  • Molecular Weight: ~76–80 kDa (dimer; glycosylated homodimer ~152–160 kDa total)
  • CAS Number: 1311689-59-6
  • PubChem CID: Not assigned (biologic; related entry for similar ActRIIB-Fc constructs)